Immunological efficacy of glypican-3 peptide vaccine in patients with advanced hepatocellular carcinoma
We have previously conducted a phase I trial to test the efficacy of a glypican-3 (GPC3) peptide vaccine in patients with advanced hepatocellular carcinoma (HCC); however, its immunological mechanism of action remains unclear. Here, we report a pilot study conducted to evaluate the immunological mec...
Main Authors: | Nobuhiro Tsuchiya, Toshiaki Yoshikawa, Norihiro Fujinami, Keigo Saito, Shoichi Mizuno, Yu Sawada, Itaru Endo, Tetsuya Nakatsura |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2017-10-01
|
Series: | OncoImmunology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/2162402X.2017.1346764 |
Similar Items
-
Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors
by: Nobuhiro Tsuchiya, et al.
Published: (2018-01-01) -
Next-Generation Cancer Immunotherapy Targeting Glypican-3
by: Yasuhiro Shimizu, et al.
Published: (2019-04-01) -
Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma
by: Tsung-Chieh Shih, et al.
Published: (2020-12-01) -
Glypican-3: A Novel and Promising Target for the Treatment of Hepatocellular Carcinoma
by: Xiufeng Zheng, et al.
Published: (2022-02-01) -
Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma
by: Kevin P. Labadie, et al.
Published: (2023-04-01)